{"product_id":"retatrutide","title":"Retatrutide (Triple Agonist | GLP-1 \/ GIP \/ Glucagon | Metabolic Pathway Research)","description":"\u003ch3 class=\"additional-info-sections__item-title\"\u003eProduct Info\u003c\/h3\u003e\n\u003cp class=\"additional-info-sections__item-description\" id=\"additional-info-painfo_01KQSQ497G7DW5GNY4BXXM9HP0\" data-v-9492fc08=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eRetatrutide is an investigational synthetic peptide being studied as a \u003cstrong\u003etriple hormone receptor agonist\u003c\/strong\u003e, targeting \u003cstrong\u003eGIP, GLP-1, and glucagon receptors\u003c\/strong\u003e. This triple-action design makes it one of the most scientifically interesting compounds in current metabolic research because it engages three major pathways involved in appetite regulation, glucose control, insulin response, lipid metabolism, and energy expenditure.\u003c\/p\u003e\n\u003cp\u003eUnlike tirzepatide, which targets GIP and GLP-1, retatrutide adds glucagon receptor activity. In research, glucagon receptor activation is especially interesting because it may influence energy expenditure, fat metabolism, and liver-related metabolic pathways. This is why retatrutide is being studied not only for obesity and type 2 diabetes, but also for broader metabolic dysfunction research, including liver-fat-related outcomes. Phase 2 studies have reported meaningful weight-loss and glycemic improvements, but retatrutide remains investigational and is not an approved medication.\u003c\/p\u003e\n\u003ch3\u003ePotential benefits observed in human studies\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eVery strong body-weight reduction\u003c\/strong\u003e\u003cbr\u003eIn a phase 2 obesity trial, retatrutide produced large, dose-dependent body-weight reductions over 48 weeks, making it one of the most closely watched investigational metabolic peptides in clinical research.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTriple-pathway metabolic activity\u003c\/strong\u003e\u003cbr\u003eRetatrutide activates GIP, GLP-1, and glucagon receptors, giving researchers a way to study combined incretin and glucagon signaling in one molecule. This may help explain its strong effects on body-weight and metabolic markers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eAppetite and satiety effects\u003c\/strong\u003e\u003cbr\u003eGLP-1 and GIP receptor activity are associated with appetite signaling, food intake regulation, and satiety pathways. This makes retatrutide important for research into hunger control and long-term energy balance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePossible increase in energy expenditure\u003c\/strong\u003e\u003cbr\u003eThe added glucagon receptor activity is scientifically important because glucagon signaling may influence energy use, lipid metabolism, and fat-burning pathways. This separates retatrutide from GLP-1-only and dual GIP\/GLP-1 compounds.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eGlycemic control improvements\u003c\/strong\u003e\u003cbr\u003eIn people with type 2 diabetes, phase 2 research reported clinically meaningful improvements in glycemic control along with robust body-weight reductions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eInterest in liver-fat and metabolic dysfunction research\u003c\/strong\u003e\u003cbr\u003eRetatrutide has been highlighted in research involving obesity, type 2 diabetes, and NAFLD-related metabolic pathways, making it useful for studying how weight loss, glucose control, and liver-fat metabolism may connect.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eOnce-weekly study design\u003c\/strong\u003e\u003cbr\u003eClinical studies have evaluated retatrutide as a once-weekly injectable investigational compound, which is relevant for pharmacokinetic and long-acting peptide research.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePotential next-generation metabolic research model\u003c\/strong\u003e\u003cbr\u003eBecause it targets three receptors instead of one or two, retatrutide is often viewed as a next-generation research compound for studying multi-receptor metabolic signaling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eLimitations and risks observed in human studies\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eStill investigational\u003c\/strong\u003e\u003cbr\u003eRetatrutide is not currently an approved medication. It is still being evaluated in clinical development, so its full long-term safety profile is not yet established.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eGastrointestinal side effects may occur\u003c\/strong\u003e\u003cbr\u003eAs with GLP-1 and incretin-based compounds, nausea, vomiting, diarrhea, constipation, reduced appetite, and abdominal discomfort are commonly discussed side effects in this class of research.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePotential for excessive weight loss\u003c\/strong\u003e\u003cbr\u003eBecause retatrutide has shown strong body-weight effects in studies, researchers and clinicians monitor concerns such as excessive weight reduction, loss of lean mass, nutritional issues, or tolerability problems.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMore complex mechanism\u003c\/strong\u003e\u003cbr\u003eTriple receptor activity may make results harder to interpret compared with single GLP-1 or dual GIP\/GLP-1 agonists. Effects may vary depending on dose, receptor expression, study population, and metabolic condition.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eHuman use requires strict medical supervision\u003c\/strong\u003e\u003cbr\u003eSince retatrutide is investigational and not approved, it should not be used outside proper clinical research settings. Research-grade or unapproved products should not be used in humans.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eWebsite-safe closing line\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHuman clinical data on retatrutide is scientifically promising, especially for body-weight, glucose-control, and metabolic-pathway research. However, retatrutide remains investigational and should only be studied under appropriate research conditions. Sterile Labs products are strictly for research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"My Store","offers":[{"title":"Vial \/ 10mg","offer_id":51941113266464,"sku":null,"price":1800.0,"currency_code":"PHP","in_stock":true},{"title":"Vial \/ 15mg","offer_id":51941113299232,"sku":null,"price":2100.0,"currency_code":"PHP","in_stock":true},{"title":"Vial \/ 30mg","offer_id":51941113332000,"sku":null,"price":2700.0,"currency_code":"PHP","in_stock":true},{"title":"Pen \/ 15mg","offer_id":51941113364768,"sku":null,"price":3900.0,"currency_code":"PHP","in_stock":true},{"title":"Pen \/ 30mg","offer_id":51941113397536,"sku":null,"price":4400.0,"currency_code":"PHP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1010\/5205\/5840\/files\/63dc7560-b312-460e-a8f7-e3222dbd565e.png?v=1783190539","url":"https:\/\/sterilelabs.shop\/products\/retatrutide","provider":"Sterile Labs","version":"1.0","type":"link"}